• 1. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 2. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 3. Empowering microfluidics by micro-3D printing and solution-based mineral coating?
  Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849
• 4. Excimer–monomer switch: a reaction-based approach for selective detection of fluoride?
  Qiao Song,Angela Bamesberger,Lingyun Yang,Haley Houtwed,Haishi Cao Analyst, 2014,139, 3588-3592
• 5. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130

Introduction to 5-aza-spiro[2.5]octane hydrochloride (CAS No. 1797157-33-5)

5-aza-spiro[2.5]octane hydrochloride is a compound of significant interest in the field of medicinal chemistry, particularly for its potential applications in the development of therapeutic agents. This compound, identified by its Chemical Abstracts Service (CAS) number 1797157-33-5, belongs to a class of spirocyclic aza compounds that have garnered attention due to their unique structural and pharmacological properties. The hydrochloride salt form enhances its solubility and bioavailability, making it a promising candidate for further investigation in drug discovery and development.

The spirocyclic structure of 5-aza-spiro[2.5]octane hydrochloride contributes to its distinct chemical and biological characteristics. Spirocyclic compounds are known for their rigid framework, which can influence the conformational flexibility and binding affinity of the molecule. The presence of an azacycloalkane moiety introduces nitrogen atoms into the ring system, which can participate in hydrogen bonding interactions and modulate the compound's pharmacokinetic profile. These features make it an attractive scaffold for designing molecules with specific biological activities.

In recent years, there has been growing interest in aza-spiro compounds due to their potential as scaffolds for small-molecule drugs. The nitrogen atom in the azacycloalkane ring can serve as a hydrogen bond acceptor, enhancing interactions with biological targets such as enzymes and receptors. This has led to the exploration of 5-aza-spiro[2.5]octane hydrochloride as a lead compound for various therapeutic applications, including oncology, inflammation, and neurodegenerative diseases.

One of the most compelling aspects of 5-aza-spiro[2.5]octane hydrochloride is its structural versatility. Medicinal chemists have leveraged this scaffold to develop derivatives with enhanced potency and selectivity. For instance, modifications at the nitrogen or carbon positions of the spirocycle can alter the compound's pharmacological profile, allowing for fine-tuning of its biological activity. This adaptability has made it a valuable tool in the quest to discover novel therapeutic agents.

Recent studies have highlighted the potential of 5-aza-spiro[2.5]octane hydrochloride in modulating enzyme activity, particularly in pathways relevant to cancer and inflammation. The compound has been shown to interact with various targets, including kinases and transcription factors, which play crucial roles in disease pathogenesis. By inhibiting or activating these targets, 5-aza-spiro[2.5]octane hydrochloride and its derivatives may offer new avenues for treating a range of diseases.

The synthesis of 5-aza-spiro[2.5]octane hydrochloride presents unique challenges due to its complex spirocyclic structure. However, advances in synthetic methodology have made it more feasible to produce this compound on a scalable basis. Techniques such as transition-metal-catalyzed reactions and asymmetric synthesis have been employed to construct the spirocycle with high efficiency and selectivity. These advancements have opened up new possibilities for exploring the therapeutic potential of this class of compounds.

The pharmacokinetic properties of 5-aza-spiro[2.5]octane hydrochloride are also an area of active investigation. Understanding how this compound is absorbed, distributed, metabolized, and excreted (ADME) is crucial for optimizing its therapeutic efficacy and safety profile. Preclinical studies have begun to elucidate these parameters, providing insights into how 5-aza-spiro[2.5]octane hydrochloride behaves within biological systems.

In conclusion, 5-aza-spiro[2.5]octane hydrochloride (CAS No. 1797157-33-5) represents a promising scaffold for drug discovery with significant potential in various therapeutic areas. Its unique structural features, combined with its pharmacological versatility, make it an attractive candidate for further development. As research continues to uncover new applications for this compound, it is likely to play an increasingly important role in the advancement of medicinal chemistry.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)